Tag : PROSTATE-SPECIFIC ANTIGEN

NEWS AND PERSPECTIVE

Low on-treatment PSA predicts improved long-term survival in advanced prostate cancer
A STAMPEDE trial analysis confirmed that achieving an on-treatment prostate-specific antigen (PSA) ‭≤0.2ng/mL as early as 6 weeks predicts favorable long-term survival in advanced prostate cancer. However, baseline metastatic volume and nodal status remain heavily prognostic, indicating that combining imaging and PSA response optimizes survival predictions.‬‬‬
CONFERENCE UPDATE

PSA level post-treatment offers prognostic insight in mHSPC: Real-world analysis of the IRONMAN registry
Dr. Tan Chih Kiang

Consultant Clinical Oncologist, Hospital Picaso, Selangor, Malaysia